{"id":1842,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2016-08-11","marketCap":1173.749755859375,"name":"Protagonist Therapeutics Inc","phone":"15104740170","outstanding":57.68000030517578,"symbol":"PTGX","website":"https://www.protagonist-inc.com/","industry":"Biotechnology"},"price":19.8775,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"Historical Price-to-Earnings (P/E) Ratio Trends of Protagonist Therapeutics Inc","date":"2023-12-14","url":"/posts/2023/12/14/PTGX","content":[{"section":"P/E Ratio Definition","text":"The price-to-earnings (P/E) ratio is a financial metric that measures the valuation of a company's stock relative to its earnings. It is calculated by dividing the market price per share by the earnings per share (EPS) over a specific period."},{"section":"Importance for Investors","text":"The P/E ratio is commonly used by investors to assess the relative value of a stock and determine if it is overvalued or undervalued. A high P/E ratio may indicate overvaluation, suggesting that investors are willing to pay a premium for future growth expectations. Conversely, a low P/E ratio may suggest undervaluation, indicating that the stock may be a good investment opportunity."},{"section":"Historical P/E Ratio Trends of Protagonist Therapeutics Inc","text":"Here is a table depicting the historical P/E ratio trends of Protagonist Therapeutics Inc stock over the past five years:"},{"section":"Year","text":"P/E Ratio"},{"section":"Year 1","text":"P/E Ratio 1"},{"section":"Year 2","text":"P/E Ratio 2"},{"section":"Year 3","text":"P/E Ratio 3"},{"section":"Year 4","text":"P/E Ratio 4"},{"section":"Year 5","text":"P/E Ratio 5"},{"section":"Significance for Investors","text":"By analyzing the historical P/E ratio trends of Protagonist Therapeutics Inc, investors can gain insights into the market's perception of the company's growth prospects. If the P/E ratio has consistently been high, it may indicate positive market sentiment and anticipated future earnings growth. Conversely, a declining or low P/E ratio could suggest concerns about the company's performance or industry headwinds. Investors should consider the P/E ratio in combination with other fundamental and qualitative factors before making investment decisions."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1702470600,"headline":"Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis","id":124484504,"image":"https://media.zenfs.com/en/accesswire.ca/92bacf5261edc19d0cebc2604c32c6f0","symbol":"PTGX","publisher":"Yahoo","summary":"NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. (\"Protagonist\" or the \"Company\") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to ...","url":"https://finance.yahoo.com/news/protagonist-earns-10-million-payment-123000407.html"},{"category":"company","date":1702457304,"headline":"Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals","id":124483006,"image":"","symbol":"PTGX","publisher":"Finnhub","summary":"NEWARK - Protagonist Therapeutics, Inc. announced details from five abstracts at the American Society of Hematology 2023 Annual Meeting, including an oral presentation with two-year follow up data...","url":"https://finnhub.io/api/news?id=510cfb6f045f634cca1cdad03f16537d887f192576736658683572705139cb35"},{"category":"company","date":1702449660,"headline":"Protagonist earns $10M payment for milestone in Phase 2b ANTHEM-UC study","id":124489356,"image":"","symbol":"PTGX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3254906038"},{"category":"company","date":1702363800,"headline":"Protagonist Therapeutics reports two-year follow up data from REVIVE study","id":124471759,"image":"","symbol":"PTGX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253130605"},{"category":"company","date":1702294560,"headline":"Protagonist Therapeutics Earns Buy Rating on Strong Rusfertide Data and Favorable Safety Profile","id":124459122,"image":"","symbol":"PTGX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3252770397"},{"category":"company","date":1702037340,"headline":"Protagonist Therapeutics: On A Ship That Could Be About To Sail","id":124396315,"image":"","symbol":"PTGX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247401512"},{"category":"company","date":1702029900,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124388899,"image":"","symbol":"PTGX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247953037"},{"category":"company","date":1701862320,"headline":"Protagonist Therapeutics Breaks Above 200-Day Moving Average - Bullish for PTGX","id":124337757,"image":"","symbol":"PTGX","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244314735"},{"category":"company","date":1701858060,"headline":"December 2024 Options Now Available For Protagonist Therapeutics (PTGX)","id":124337758,"image":"","symbol":"PTGX","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244213199"},{"category":"company","date":1701840060,"headline":"Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), ZyVersa Therapeutics (ZVSA) and Mainz Biomed B.V. (MYNZ)","id":124337759,"image":"","symbol":"PTGX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3243850672"},{"category":"company","date":1701767760,"headline":"Buy Rating for Protagonist Therapeutics: Market Dominance and Royalty Windfall from JNJ-2113â€™s Potential","id":124311422,"image":"","symbol":"PTGX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242273286"}]}